---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-24-000026"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:17:12.877450+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio Q1 net loss $43.9M, cash $370M; Phase 2b data for ANB032 by YE2024, $50M royalty monetization

## Summary
- Q1 2024 net loss $43.9M ($1.64/share) vs $44.3M ($1.58/share) in Q1 2023; revenue $7.2M from Jemperli royalties.
- Cash, cash equivalents, investments total $370.1M (excl. $50M monetization); cash runway through year-end 2026.
- Phase 2b trial for ANB032 (BTLA agonist) in atopic dermatitis enrolling; top-line data expected by year-end 2024.
- Phase 2b trial for rosnilimab (PD-1 agonist) in RA and Phase 2 trial in UC enrolling; top-line data mid-2025 and H1 2026.
- Announced $50M capped non-recourse royalty monetization from Sagard for additional Jemperli royalties; positive Phase 3 imsidolimab results in GPP.

## SEC filing metadata
- accession: 0001370053-24-000026
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000026/0001370053-24-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000026/anab-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-24-000026
- JSON: https://secwatch.observer/filing/0001370053-24-000026.json
- Plain text: https://secwatch.observer/filing/0001370053-24-000026.txt

## Key facts
- Earnings Releases
  ANAPTYSBIO, INC reported first quarter ended March 31, 2024 results: revenue $7.2 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $7.2 million
  - Result: reported results
  source text: activities as well as a one-time non-operating cash payment of $10.9 million during the quarter. ◦ Reiterating cash runway through year-end 2026 • Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three months ended March 31, 2023. The change is due primarily to increased royalties
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000026/0001370053-24-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.